
Title: PET/CT for Cancer Diagnosis, Staging and Prognosis



Jiaqiong Wang, M.D., Ph.D. (Guest Editor)

The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami USA E-mail: jiaqiongwangmd@gmail.com

Proposal

2-deoxy-2-[18F]fluoroglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) is a valuable imaging study in the diagnosis of cancer, staging and restaging disease, providing valuable information about the patient's response to therapeutic regimen, as well as in predicting prognosis. In different tumor types, however, there is a great variation in the sensitivity and specificity of FDG PET/CT. It is necessary to optimize 18F-FDG-PET image interpretation technique and quantitative parameters to accurately reflect clinical and histological characteristics of tumor.

We invite authors to submit case reports, original research, clinical trials as well as review articles to this special issue in Journal of Cancer Research Updates that will help improve the value of FDG-PET/CT in the diagnosis of cancer, the monitor of treatment response as well as in patient follow up.

Potential topics include, but are not limited to:

- 1. Case reports on FDG PET/CT in monitoring therapeutic response (e.g., chemotherapy, radiation therapy and other adjuvant therapy)
- 2. Clinical trials on FDG PET/CT for cancer staging and restaging
- 3. The prognostic value of FDG PET/CT in cancer patients
- 4. Novel quantitative parameters and/or criteria of 18F-FDG-PET in cancer diagnosis and the evaluation of metastasis
- 5. Novel radiopharmaceuticals in PET/CT cancer imaging

Before submission authors should carefully read over the journal's Author Guidelines, which are located at http://www.lifescienceglobal.com/publish-with-us/guidelines-for-authors. Prospective authors should submit an electronic copy of their complete manuscript through the journal Manuscript Tracking System at http://www.lifescienceglobal.com/pms/index.php/jcru